Schizophrenia Clinical Trials

Find Schizophrenia Clinical Trials Near You

A Pilot Feasibility Study of Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study to find out whether a type of non-invasive electrical brain stimulation called transcranial electrical stimulation with temporal interference (TES-TI) can temporarily change brain activity during sleep-especially sleep spindles (brain rhythms in the \ 8-16 Hz range). The investigators are focusing on the thalamus, a deep brain region that helps coordinate brain activity during non-REM sleep. Sleep spindles are often reduced in schizophrenia, so this study is to see whether TES-TI can change spindle activity in individuals with schizophrenia spectrum disorders (SSD) and in healthy adults. To study this, a structural MRI scan will be used to customize where the stimulation electrodes are placed, and then TES-TI will be applied during one of two overnight sleep lab visits while brain activity is recorded with high-density EEG and standard sleep sensors. The other overnight is a baseline/control night during which only sham stimulation is delivered. The goal is to determine whether TES-TI during sleep can increase spindle-frequency activity in this population.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: t
View:

• U.S. citizen or holding permanent resident status

• English-speaking

• DSM-5 schizophrenia spectrum disorder (SSD) diagnosis, defined as schizophrenia, schizoaffective disorder, or schizophreniform disorder (confirmed by clinical interview and/or chart review)

• Chronic illness, defined as diagnosis of SSD for at least 1 year

• Clinically stable outpatient (no psychiatric hospitalization in past 6 months; no change in antipsychotic medication in the past 6 weeks)

• Medically healthy (based on self-report and study team review)

• Matched to SSD participants on age (±5 years) and sex

Locations
United States
Wisconsin
University of Wisconsin
RECRUITING
Madison
Contact Information
Primary
ONSETS Study
onsets@psychiatry.wisc.edu
608-263-4313
Time Frame
Start Date: 2026-09
Estimated Completion Date: 2027-12
Participants
Target number of participants: 20
Treatments
Experimental: Participants with SSD
Experimental: Healthy Controls
Related Therapeutic Areas
Sponsors
Collaborators: Alkermes, Inc.
Leads: University of Wisconsin, Madison

This content was sourced from clinicaltrials.gov